Webcast - Live
Q2 2010 Penwest Pharmaceuticals Earnings Conference Call
08/04/10 at 11:00 a.m.ET
Profile
Penwest develops pharmaceutical products based on the application of innovative oral drug delivery technologies.
Featured Report
2009 Annual Report
2010 Proxy Statement and Annual Meeting Information

For questions concerning how to submit your vote or to receive proxy materials, please contact MacKenzie Partners, Inc toll free at 800-322-2885 or collect at 212-929-5500 or email: proxy@mackenziepartners.com

Stock Quote
Stock Quote Disclaimer
PPCO (PPCO)
ExchangeNASDAQ (US Dollar)
Price$3.38
Change (%) Stock is Down 0.1 (2.87%)
Volume130,228
Data as of 07/30/10 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore News >>
DateTitle 
07/28/10Penwest to Present at Upcoming ConferencesPrinter Friendly Version
07/27/10Penwest Second Quarter 2010 Financial Results Conference CallPrinter Friendly Version
06/30/10Penwest Announces That the Results of Its Annual Meeting Have Been CertifiedPrinter Friendly Version
06/22/10Penwest Announces Preliminary Vote Count at Annual MeetingPrinter Friendly Version
Contact Information
Investor Relations
Kekst & Company, Inc.
437 Madison Avenue
New York, NY 10022
Ph: 212-521-4800
Investor@penwest.com

Accountants
Ernst & Young LLP
1111 Summer St
Stamford, CT 06905
Ph: 203-674-3000

Legal
WilmerHale
60 State St
Boston, MA 02109
Ph: 617-526-6000

Transfer Agent
Mellon Investor Services LLC
111 Founders Plaza
Eleventh Floor
E Hartford, CT 06108
Ph: 800-288-9541

 

2008 Penwest Pharmaceuticals Co.
Terms and Conditions, Privacy Statement, & Safe Harbor